末梢血単核細胞 (PBMC) 市場：製品・用途・技術・供給源・地域別の機会および予測 (2018-2032年)

世界の末梢血単核細胞 (PBMC) の市場規模は、2024年の3億3,591万米ドルから、予測期間中はCAGR 10.09％で推移し、2032年には7億2,921万米ドルに成長すると予測されています。

PBMCの需要は、免疫学、感染症研究、血液学、創薬など、幅広いバイオメディカル研究分野に不可欠な存在であることから、その需要が大きく高まっています。リンパ球や単球を含むこれらの多機能細胞は、疾患メカニズムの解明、治療薬の評価、新たな細胞ベース治療法の開発において極めて重要です。

PBMC市場は、細胞免疫学に対する研究者の理解の深まりと、分離、凍結保存、培養技術の進歩によって急速に発展しています。慢性疾患や感染症の世界的増加、バイオ医薬品研究への大規模な投資が高品質PBMCへの需要を押し上げています。本市場では、凍結保存PBMC、新鮮PBMC、特殊な分離・生存率評価キットなど、さまざまな製品が提供されています。密度勾配遠心法やロイコアフェレーシス（白血球分離技術）などの最新技術により、PBMCの分離純度および収率が向上し、複雑な研究や臨床応用における有用性がさらに高まっています。また、細胞ベースアッセイの採用拡大や、個別化医療の進展も市場成長を後押ししています。地域別では、北米が高度な研究インフラ、大規模な研究開発投資、主要企業の存在感により市場をリードしていますが、アジア太平洋地域もバイオテクノロジー産業の台頭と医療支出の増加を背景に有望な成長が期待されています。

さらに、PBMC市場には、細胞製品の供給だけでなく、特殊な試薬やラボサービスを提供する主要企業が参入しています。今後もバイオテクノロジーの進歩、ライフサイエンス分野への資金増加、研究者・臨床医の知識向上などにより、PBMC市場の成長は持続すると見込まれます。

当レポートでは、世界の末梢血単核細胞 (PBMC) の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分別の詳細分析、ケーススタディ、市場成長への影響因子の分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の末梢血単核細胞 (PBMC) 市場の展望

• 市場規模の分析・予測
• 市場シェアの分析・予測
  • 製品別
    • 凍結保存または冷凍PBMC
    • 培養または新鮮PBMC
    • PBMC分離および生存率キット
  • 用途別
    • 免疫学
    • 血液学
    • ワクチン開発
    • 毒物学
    • 感染症
    • その他
  • 技術別
    • 密度勾配遠心法
    • ロイコアフェレーシス（白血球分離法）
    • その他
  • 由来別
    • ヒト
    • 動物
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア分析（上位5社およびその他）
• 市場マップ分析

第5章 北米の末梢血単核細胞 (PBMC) 市場の展望

• 市場規模の分析・予測
• 市場シェアの分析・予測
• 国別市場評価
  • カナダ
  • メキシコ

第6章 アジア太平洋の末梢血単核細胞 (PBMC) 市場の展望

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア

第7章 欧州の末梢血単核細胞 (PBMC) 市場の展望

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• ポーランド

第8章 中東・アフリカの末梢血単核細胞 (PBMC) 市場の展望

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ

第9章 南米の末梢血単核細胞 (PBMC) 市場の展望

• ブラジル
• アルゼンチン

第10章 需給分析

第11章 輸出入分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場促進要因
• 市場の課題

第17章 規制の枠組み

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 上位5社の競合マトリックス
• 上位5社のSWOT分析
• 上位10社の情勢
  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • Bio-Rad Laboratories Inc.
  • Corning Incorporated
  • Thermo Fisher Scientific Inc.
  • BioIVT LLC
  • Ixcells Biotechnologies USA, Inc.
  • Precision Medicine Group, LLC
  • Biopredic International
  • CGT Global LLC

第21章 戦略的提言

第22章 調査会社について・免責事項

List of Tables

• Table 1: Table 1: Top 10 Exporting Countries (Value), USD Thousand, 2020-2024
• Table 2: Top 10 Importing Countries (Value), USD Thousand, 2020-2024
• Table 3: Regulatory Compliance Framework for Peripheral Blood Mononuclear Cells (PBMCs)
• Table 4: Globally R

List of Figures

• Figure 1: Global Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 2: Global Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 3: Global Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 4: Global Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 5: Global Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 6: Global Peripheral Blood Mononuclear Cells Market Share, By Region, By Value, 2018-2032F
• Figure 7: Global Peripheral Blood Mononuclear Cells Market Share, By Company, By Value, 2024
• Figure 8: Global Peripheral Blood Mononuclear Cells Market Map, By Product, By Value, 2024
• Figure 9: Global Peripheral Blood Mononuclear Cells Market Map, By Application, By Value, 2024
• Figure 10: Global Peripheral Blood Mononuclear Cells Market Map, By Techniques, By Value, 2024
• Figure 11: Global Peripheral Blood Mononuclear Cells Market Map, By Source, By Value, 2024
• Figure 12: Global Peripheral Blood Mononuclear Cells Market Map, By Region, By Value, 2024
• Figure 13: North America Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 14: North America Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 15: North America Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 16: North America Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 17: North America Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 18: North America Peripheral Blood Mononuclear Cells Market Share, By Country, By Value, 2018-2032F
• Figure 19: United States Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 20: United States Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 21: United States Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 22: United States Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 23: United States Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 24: Canada Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 25: Canada Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 26: Canada Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 27: Canada Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 28: Canada Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 29: Brazil Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 30: Brazil Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 31: Brazil Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 32: Brazil Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 33: Brazil Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 34: Europe Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 35: Europe Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 36: Europe Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 37: Europe Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 38: Europe Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 39: Europe Peripheral Blood Mononuclear Cells Market Share, By Country, By Value, 2018-2032F
• Figure 40: Germany Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 41: Germany Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 42: Germany Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 43: Germany Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 44: Germany Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 45: France Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 46: France Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 47: France Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 48: France Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 49: France Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 50: United Kingdom Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 51: United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 52: United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 53: United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 54: United Kingdom Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 55: Italy Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 56: Italy Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 57: Italy Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 58: Italy Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 59: Italy Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 60: Spain Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 61: Spain Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 62: Spain Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 63: Spain Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 64: Spain Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 65: Russia Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 66: Russia Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 67: Russia Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 68: Russia Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 69: Russia Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 70: Poland Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 71: Poland Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 72: Poland Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 73: Poland Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 74: Poland Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 75: Netherlands Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 76: Netherlands Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 77: Netherlands Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 78: Netherlands Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 79: Netherlands Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 80: Asia-Pacific Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 81: Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 82: Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 83: Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 84: Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 85: Asia-Pacific Peripheral Blood Mononuclear Cells Market Share, By Country, By Value, 2018-2032F
• Figure 86: China Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 87: China Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 88: China Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 89: China Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 90: China Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 91: Japan Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 92: Japan Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 93: Japan Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 94: Japan Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 95: Japan Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 96: India Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 97: India Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 98: India Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 99: India Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 100: India Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 101: South Korea Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 102: South Korea Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 103: South Korea Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 104: South Korea Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 105: South Korea Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 106: Australia Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 107: Australia Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 108: Australia Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 109: Australia Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 110: Australia Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 111: Indonesia Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 112: Indonesia Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 113: Indonesia Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 114: Indonesia Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 115: Indonesia Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 116: Vietnam Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 117: Vietnam Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 118: Vietnam Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 119: Vietnam Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 120: Vietnam Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 121: Middle East & Africa Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 122: Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 123: Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 124: Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 125: Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 126: Middle East & Africa Peripheral Blood Mononuclear Cells Market Share, By Country, By Value, 2018-2032F
• Figure 127: Saudi Arabia Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 128: Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 129: Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 130: Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 131: Saudi Arabia Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 132: UAE Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 133: UAE Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 134: UAE Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 135: UAE Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 136: UAE Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 137: South Africa Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 138: South Africa Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 139: South Africa Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 140: South Africa Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 141: South Africa Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 142: South America Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 143: South America Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 144: South America Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 145: South America Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 146: South America Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 147: South America Peripheral Blood Mononuclear Cells Market Share, By Country, By Value, 2018-2032F
• Figure 148: Brazil Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 149: Brazil Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 150: Brazil Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 151: Brazil Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 152: Brazil Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F
• Figure 153: Argentina Peripheral Blood Mononuclear Cells Market Size, By Value (USD Million), 2018-2032F
• Figure 154: Argentina Peripheral Blood Mononuclear Cells Market Share, By Product, By Value, 2018-2032F
• Figure 155: Argentina Peripheral Blood Mononuclear Cells Market Share, By Application, By Value, 2018-2032F
• Figure 156: Argentina Peripheral Blood Mononuclear Cells Market Share, By Techniques, By Value, 2018-2032F
• Figure 157: Argentina Peripheral Blood Mononuclear Cells Market Share, By Source, By Value, 2018-2032F

Global peripheral blood mononuclear cells (PBMC) market is projected to witness a CAGR of 10.09% during the forecast period 2025-2032, growing from USD 335.91 million in 2024 to USD 729.21 million in 2032. The demand for PBMCs is significantly rising as they are crucial for a wide range of applications in biomedical research, including immunology, infectious disease studies, hematology, and drug development. These versatile cells, which include lymphocytes and monocytes, are essential for understanding disease mechanisms, testing therapeutic agents, and developing novel cell-based treatments.

The PBMC market is developing rapidly as researchers better understand cellular immunology and as technological advancements improve isolation, cryopreservation, and culture techniques. The increasing global prevalence of chronic diseases and infectious diseases, coupled with significant investments in biopharmaceutical research, drives the demand for high-quality PBMCs. The market provides various products, including cryopreserved PBMCs, fresh PBMCs, and specialized isolation and viability kits. Modern techniques such as density gradient centrifugation and leukapheresis have improved the purity and yield of PBMC isolation, enhancing their utility in complex research and clinical applications. Market growth is further driven by the rising adoption of cell-based assays and the expansion of personalized medicine initiatives. The market leader, North America, holds regional dominance because of its advanced research infrastructure, significant R&D investments, and a strong presence of key market players, yet Asia-Pacific shows promising growth because of emerging biotechnology sectors and increasing healthcare expenditures.

Moreover, the PBMC market includes main industry players who provide extensive cell products alongside specialized reagents and laboratory services. PBMC market growth will persist in the future due to new biotechnological developments, increased funding for life sciences, and rising knowledge among researchers and clinicians. For instance, in October 2024, Lonza Group AG announced the expansion of its cell and gene therapy manufacturing facility in Houston, Texas, to meet the growing demand for advanced therapeutic products, which often rely on high-quality human cells like PBMCs for research and manufacturing.

Growing Demand in Immunotherapy and Vaccine Development Drives Market Share

The growing demand for peripheral blood mononuclear cells (PBMCs) in immunotherapy and vaccine development has significantly contributed to the increased market share of the PBMC market. PBMCs are indispensable for studying immune responses, developing cell-based therapies, and evaluating vaccine efficacy. The global rise in immune-mediated diseases, cancers, and the continuous threat of emerging infectious diseases has intensified research efforts into novel treatments. PBMCs provide a critical source of immune cells for understanding disease pathology and designing targeted interventions. The increasing number of clinical trials for immunotherapies, such as CAR T-cell therapy and checkpoint inhibitors, directly fuels the demand for precisely characterized and high-quality PBMCs. This has led to increased sales of specialized PBMC products and isolation kits. The PBMC market maintains strong market growth and has expanded its market share throughout the world due to their integral role in advancing these critical therapeutic areas.

For instance, in September 2024, Precision Medicine Group, LLC announced a new partnership with a leading biopharmaceutical company to provide comprehensive biomarker services, including the isolation and analysis of PBMCs, for their oncology clinical trials, highlighting the critical role of PBMCs in precision medicine.

Advancements in PBMC Isolation and Preservation Techniques Fuel Market Growth

The global peripheral blood mononuclear cells (PBMC) market experiences substantial expansion because of ongoing product innovations in PBMC isolation and preservation techniques. Modern methods, including advanced density gradient media, automated cell separation systems, and improved cryopreservation protocols, now provide better purity, viability, and recovery of PBMCs, leading to enhanced research outcomes and clinical applications. Healthcare providers and researchers use modern therapeutic agents, which consist of specialized cryopreservation solutions and viability reagents, to maintain cellular integrity and functionality, improving therapeutic results while decreasing cell loss during storage and transport. The integration of flow cytometry with molecular testing methods enables quick and exact characterization of PBMC subsets for various applications, which includes drug screening and disease monitoring. Modern technology allows PBMC-based research to deliver better results while simultaneously building greater confidence among researchers and clinicians about immediate treatment approaches. The growing availability of specialized PBMC products through biobanks and contract research organizations (CROs) helps expand market reach which further drives growth. The market will experience ongoing expansion across developed and emerging regions because innovation continues.

Additionally, to support the advancement in the PBMC market, regulatory bodies also take initiatives by standardizing collection and processing guidelines. For instance, in May 2025, the International Society for Cell & Gene Therapy (ISCT) released updated guidelines for the collection, processing, and cryopreservation of human cellular material, including PBMCs, to ensure consistency and quality for clinical research.

Cryopreserved or Frozen PBMC Holds the Largest Global Peripheral Blood Mononuclear Cells Market Share

The peripheral blood mononuclear cells market features Cryopreserved or Frozen PBMC as its leading market segment because researchers and clinicians highly value their long-term stability and convenience for longitudinal studies. These cells offer critical advantages, allowing for batch processing, retrospective analysis, and consistency across experiments, making them ideal for large-scale research projects and multi-center clinical trials. The increasing need for standardized, readily available cell sources for drug discovery, biomarker identification, and cell therapy development has significantly boosted the demand for cryopreserved PBMCs. Biobanks and commercial suppliers have expanded their offerings of well-characterized cryopreserved PBMC cohorts, ensuring reliable access for diverse research applications. The ability to store and transport these cells without compromising their viability or functionality has further solidified their dominance. Cryopreserved or Frozen PBMCs maintain the highest market share because of these combined market factors.

Additionally, to enhance the accessibility and quality of cryopreserved PBMCs, companies are expanding their bioprocessing capabilities and global distribution networks. For instance, in November 2024, BioIVT LLC announced the expansion of its human biospecimen collection and processing capabilities, specifically increasing its capacity for providing high-quality cryopreserved PBMCs for drug discovery and development.

North America Dominates the Global Peripheral Blood Mononuclear Cells Market Size

North America dominates the peripheral blood mononuclear cells (PBMC) market because of multiple essential elements. The region has several factors that make it the leading PBMC market. Significant research and development (R&D) investments exist at an elevated level throughout this region since academic institutions, pharmaceutical companies, and biotechnology firms show growing attention to advanced cellular research. These organizations now recognize the increasing utility of PBMCs in areas like personalized medicine, oncology, and infectious disease research, which drives their search for specialized PBMC products and services. Market growth receives substantial support from advanced biotechnology infrastructure and technological innovations. The establishment of major biopharmaceutical companies and well-funded research institutions enables quicker development of new PBMC isolation techniques, preservation methods, and cell-based assays. Market demand increases because researchers pursue cutting-edge therapies, while the prevalence of chronic diseases and the need for new drug targets become more common. Regulatory agencies, together with a growing number of skilled researchers and clinicians, work to increase the availability of services. The combination of these elements establishes North America as a leading force in the PBMC market which pushes forward both innovation and market expansion across the region.

Additionally, the growing funding for life sciences research in the United States also helps to dominate this region by increasing demand for high-quality PBMCs. For instance, in March 2025, according to the National Institutes of Health (NIH) funding data, total biomedical research funding increased by 7% compared to 2024, with a significant portion allocated to cell-based research and immunotherapy, directly benefiting the PBMC market.

Impact of Bioresearch Funding Cuts on Global Peripheral Blood Mononuclear Cells Market

Reductions in government and private funding for bioresearch can significantly impact the global peripheral blood mononuclear cells (PBMC) market. The initial impact of funding cuts causes a decrease in research grants and R&D budgets, which results in reduced purchasing power for academic institutions and biotechnology companies that rely heavily on PBMCs for their studies. This situation might limit the scope of ongoing research, delay new drug development, and impede the adoption of advanced cellular technologies. The slowdown in research activities could lead to a decline in demand for PBMC products, affecting suppliers and manufacturers. However, it might also force companies to innovate more cost-effective isolation and preservation methods or to seek alternative funding sources. The total market effect depends on the duration and severity of the funding cuts, together with the ability of market players to adapt to changing economic landscapes. The effects on scientific advancement and the market.

Key Players Landscape and Outlook

Continuous innovation characterized the landscape of the peripheral blood mononuclear cells market. Key players have established their strong presence in the PBMC market through strategic partnerships, collaboration, and acquisition and merger to lead the market. The future looks optimistic because growing demand from therapeutic and research applications, coupled with increasing investments in life sciences, creates steady market expansion.

In August 2024, Charles River Laboratories International, Inc. acquired a specialized cell therapy CRO, enhancing its capabilities in providing high-quality human PBMC services for preclinical and clinical research, expanding its offering in the cell and gene therapy space.

In July 2023, Thermo Fisher Scientific Inc. launched a new automated system for high-throughput isolation of PBMCs from blood samples, aiming to streamline laboratory workflows and improve the consistency and yield of isolated cells for various research applications.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Product
    • 4.2.1.1. Cryopreserved or Frozen PBMC
    • 4.2.1.2. Cultured or Fresh PBMC
    • 4.2.1.3. PBMC Isolation and Viability Kits
  • 4.2.2. By Application
    • 4.2.2.1. Immunology
    • 4.2.2.2. Hematology
    • 4.2.2.3. Vaccine Development
    • 4.2.2.4. Toxicology
    • 4.2.2.5. Infectious Disease
    • 4.2.2.6. Others
  • 4.2.3. By Techniques
    • 4.2.3.1. Density Gradient Centrifugation
    • 4.2.3.2. Leukapheresis
    • 4.2.3.3. Others
  • 4.2.4. By Source
    • 4.2.4.1. Human
    • 4.2.4.2. Animal
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Product Type
  • 4.3.2. By Application
  • 4.3.3. By Techniques
  • 4.3.4. By Source
  • 4.3.5. By Region

5. North America Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Product
    • 5.2.1.1. Cryopreserved or Frozen PBMC
    • 5.2.1.2. Cultured or Fresh PBMC
    • 5.2.1.3. PBMC Isolation and Viability Kits
  • 5.2.2. By Application
    • 5.2.2.1. Immunology
    • 5.2.2.2. Hematology
    • 5.2.2.3. Vaccine Development
    • 5.2.2.4. Toxicology
    • 5.2.2.5. Infectious Disease
    • 5.2.2.6. Others
  • 5.2.3. By Techniques
    • 5.2.3.1. Density Gradient Centrifugation
    • 5.2.3.2. Leukapheresis
    • 5.2.3.3. Others
  • 5.2.4. By Source
    • 5.2.4.1. Human
    • 5.2.4.2. Animal
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Product
        • 5.3.1.2.1.1. Cryopreserved or Frozen PBMC
        • 5.3.1.2.1.2. Cultured or Fresh PBMC
        • 5.3.1.2.1.3. PBMC Isolation & Viability Kits
      • 5.3.1.2.2. By Application
        • 5.3.1.2.2.1. Immunology
        • 5.3.1.2.2.2. Hematology
        • 5.3.1.2.2.3. Vaccine Development
        • 5.3.1.2.2.4. Toxicology
        • 5.3.1.2.2.5. Infectious Disease
        • 5.3.1.2.2.6. Others
      • 5.3.1.2.3. By Techniques
        • 5.3.1.2.3.1. Density Gradient Centrifugation
        • 5.3.1.2.3.2. Leukapheresis
        • 5.3.1.2.3.3. Others
      • 5.3.1.2.4. By Source
        • 5.3.1.2.4.1. Human
        • 5.3.1.2.4.2. Animal
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F

• 6.1. India
• 6.2. China
• 6.3. Japan
• 6.4. Australia
• 6.5. Vietnam
• 6.6. South Korea
• 6.7. Indonesia

7. Europe Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Poland

8. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F

• 8.1. Saudi Arabia
• 8.2. UAE
• 8.3. South Africa

9. South America Peripheral Blood Mononuclear Cells Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Regulatory Framework

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Lonza Group AG
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Charles River Laboratories International, Inc.
  • 20.3.3. Bio-Rad Laboratories Inc.
  • 20.3.4. Corning Incorporated
  • 20.3.5. Thermo Fisher Scientific Inc.
  • 20.3.6. BioIVT LLC
  • 20.3.7. Ixcells Biotechnologies USA, Inc.
  • 20.3.8. Precision Medicine Group, LLC
  • 20.3.9. Biopredic International
  • 20.3.10. CGT Global LLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer